Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Akebia Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES
Ticker
Exchange
SIC #
Website
Latest Ticker
AKBA
Nasdaq
2836
www.akebia.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Akebia Therapeutics, Inc.
H.C. Wainwright Initiates Coverage of Akebia Therapeutics (AKBA) With Buy Rating
- Jun 5th, 2025 2:33 pm
Vadadustat U.S. Patient Data from Global Phase 3 Clinical Program Published in Journal of the American Society of Nephrology
- Jun 4th, 2025 6:00 am
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Jun 2nd, 2025 2:05 pm
Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference 2025
- May 28th, 2025 6:00 am
Akebia Therapeutics Announces Three Poster Presentations at the European Renal Association Congress 2025
- May 27th, 2025 6:00 am
Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
- May 13th, 2025 6:00 am
Akebia Therapeutics First Quarter 2025 Earnings: Beats Expectations
- May 10th, 2025 6:35 am
Akebia Therapeutics Inc (AKBA) Q1 2025 Earnings Call Highlights: Strong Revenue Performance and ...
- May 9th, 2025 1:11 am
Akebia Therapeutics (AKBA) Q1 Earnings and Revenues Top Estimates
- May 8th, 2025 6:15 am
Akebia Therapeutics: Q1 Earnings Snapshot
- May 8th, 2025 5:18 am
Akebia Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights
- May 8th, 2025 5:00 am
Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy?
- May 1st, 2025 8:01 am
Akebia Therapeutics to Report First Quarter 2025 Financial Results and Discuss Recent Business Highlights
- May 1st, 2025 6:00 am
Why You Shouldn't Bet Against Akebia Therapeutics (AKBA) Stock
- Apr 10th, 2025 6:56 am
US High Growth Tech Stocks to Watch in 2023
- Apr 9th, 2025 5:38 am
Akebia Therapeutics Announces Positive Opinion of European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease Licensed to Averoa
- Apr 3rd, 2025 6:00 am
Akebia Therapeutics Announces Poster Presentations at NKF Spring Clinical Meetings 2025
- Mar 25th, 2025 6:00 am
Akebia Stock Drops 28% on Pricing of $50M Common Stock Offering
- Mar 21st, 2025 11:01 am
Accenture reports Q2 beat, Apple TV+ losing $1B annually: Morning Buzz
- Mar 21st, 2025 10:16 am
Why Akebia Therapeutics Inc. (AKBA) Went Down On Thursday?
- Mar 21st, 2025 5:06 am
Scroll